Larimar Therapeutics Inc (LRMR)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
Larimar Therapeutics Raises $150 Million in Underwritten Public Offering of Common Stock
Larimar Therapeutics Aims to Secure Future with Proposed Underwritten Public Offering
Larimar Therapeutics* Groundbreaking Study Shows Promise in Rare Friedreich*s Ataxia Treatment
Operating Shortfall Improves for Larimar Therapeutics Inc. in Q1 2023, Reaching $-8.887 Million
costs have been increasing at the company in the financial interval ending December 31 2022